BRST5:Volunteer Assignments and Opportunities: Difference between revisions

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 39: Line 39:
----
----
|-
|-
|Usual Ductal Hyperplasia
|Usual ductal hyperplasia
|Disease
|Disease
|
|
Line 50: Line 50:
|
|
|-
|-
|Columnar Cell Lesions, Including Flat Epithelial Atypia||Disease||
|Columnar cell lesions, including flat epithelial atypia||Disease||
|
|
|
|
Line 59: Line 59:
|
|
|-
|-
|Atypical Ductal Hyperplasia||Disease||
|Atypical ductal hyperplasia||Disease||
|
|
|
|
Line 68: Line 68:
|
|
|-
|-
|Sclerosing Adenosis||Disease||
|Sclerosing adenosis||Disease||
|
|
|
|
Line 77: Line 77:
|
|
|-
|-
|Apocrine Adenosis and Adenoma||Disease||
|Apocrine adenosis and adenoma||Disease||
|
|
|
|
Line 86: Line 86:
|
|
|-
|-
|Microglandular Adenosis||Disease||
|Microglandular adenosis||Disease||
|
|
|
|
Line 95: Line 95:
|
|
|-
|-
|Radial Scar/Complex Sclerosing Lesion||Disease||
|Radial scar/complex sclerosing lesion||Disease||
|
|
|
|
Line 104: Line 104:
|
|
|-
|-
|Tubular Adenoma||Disease||
|Tubular adenoma||Disease||
|
|
|
|
Line 113: Line 113:
|
|
|-
|-
|Lactating Adenoma||Disease||
|Lactating adenoma||Disease||
|
|
|
|
Line 122: Line 122:
|
|
|-
|-
|Ductal Adenoma||Disease||
|Ductal adenoma||Disease||
|
|
|
|
Line 131: Line 131:
|
|
|-
|-
|Pleomorphic Adenoma||Disease||
|Pleomorphic adenoma||Disease||
|
|
|
|
Line 149: Line 149:
|
|
|-
|-
|Malignant Adenomyoepithelioma||Disease||
|Malignant adenomyoepithelioma||Disease||
|
|
|
|
Line 158: Line 158:
|
|
|-
|-
|Intraductal Papilloma||Disease||
|Intraductal papilloma||Disease||
|
|
|
|
Line 167: Line 167:
|
|
|-
|-
|Papillary Ductal Carcinoma In Situ||Disease||
|Papillary ductal carcinoma in situ||Disease||
|
|
|
|
Line 176: Line 176:
|
|
|-
|-
|Encapsulated Papillary Carcinoma||Disease||
|Encapsulated papillary carcinoma||Disease||
|
|
|
|
Line 185: Line 185:
|
|
|-
|-
|Solid Papillary Carcinoma (In Situ and Invasive)||Disease||
|Solid papillary carcinoma (in situ and invasive)||Disease||
|
|
|
|
Line 194: Line 194:
|
|
|-
|-
|Invasive Papillary Carcinoma||Disease||
|Invasive papillary carcinoma||Disease||
|
|
|
|
Line 203: Line 203:
|
|
|-
|-
|Atypical Lobular Hyperplasia||Disease||
|Atypical lobular hyperplasia||Disease||
|
|
|
|
Line 212: Line 212:
|
|
|-
|-
|Lobular Carcinoma In Situ||Disease||
|Lobular carcinoma in situ||Disease||
|
|
|
|
Line 221: Line 221:
|
|
|-
|-
|Ductal Carcinoma In Situ||Disease||
|Ductal carcinoma in situ||Disease||
|
|
|
|
Line 230: Line 230:
|
|
|-
|-
|Invasive Breast Carcinoma of No Special Type||Disease||
|Invasive breast carcinoma of no special type||Disease||
|
|
|
|
Line 239: Line 239:
|
|
|-
|-
|Microinvasive Carcinoma||Disease||
|Microinvasive carcinoma||Disease||
|
|
|
|
Line 248: Line 248:
|
|
|-
|-
|Invasive lobular Carcinoma||Disease||
|Invasive lobular carcinoma||Disease||
|
|
|
|
Line 257: Line 257:
|
|
|-
|-
|Tubular Carcinoma||Disease||
|Tubular carcinoma||Disease||
|
|
|
|
Line 266: Line 266:
|
|
|-
|-
|Cribriform Carcinoma||Disease||
|Cribriform carcinoma||Disease||
|
|
|
|
Line 275: Line 275:
|
|
|-
|-
|Mucinous Carcinoma||Disease||
|Mucinous carcinoma||Disease||
|
|
|
|
Line 284: Line 284:
|
|
|-
|-
|Mucinous Cystadenocarcinoma||Disease||
|Mucinous cystadenocarcinoma||Disease||
|
|
|
|
Line 293: Line 293:
|
|
|-
|-
|Invasive Micropapillary Carcinoma||Disease||
|Invasive micropapillary carcinoma||Disease||
|
|
|
|
Line 302: Line 302:
|
|
|-
|-
|Carcinoma with Apocrine Differentiation||Disease||
|Carcinoma with apocrine differentiation||Disease||
|
|
|
|
Line 311: Line 311:
|
|
|-
|-
|Metaplastic Carcinoma||Disease||
|Metaplastic carcinoma||Disease||
|
|
|
|
Line 320: Line 320:
|
|
|-
|-
|[[BRST5:Acinic Cell Carcinoma|Acinic Cell Carcinoma]]||Disease||Patricija Zot
|[[BRST5:Acinic Cell Carcinoma|Acinic cell carcinoma]]||Disease||Patricija Zot
|2/28/2024
|2/28/2024
|
|
Line 329: Line 329:
|
|
|-
|-
|[[BRST5:Adenoid Cystic Carcinoma|Adenoid Cystic Carcinoma]]||Disease||Katherine Geiersbach / Jun Liao
|[[BRST5:Adenoid Cystic Carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach / Jun Liao
|10/12/02022
|10/12/02022
|11/11/2023
|11/11/2023
Line 338: Line 338:
|2021 template added
|2021 template added
|-
|-
|[[BRST5:Secretory Carcinoma|Secretory Carcinoma]]||Disease||Hui Chen / Morteza Seifi
|[[BRST5:Secretory Carcinoma|Secretory carcinoma]]||Disease||Hui Chen / Morteza Seifi
|10/12/2022
|10/12/2022
|11/11/2023
|11/11/2023
Line 347: Line 347:
|2021 template added
|2021 template added
|-
|-
|Mucoepidermoid Carcinoma||Disease||
|Mucoepidermoid carcinoma||Disease||
|
|
|
|
Line 356: Line 356:
|
|
|-
|-
|Polymorphous Adenocarcinoma||Disease||
|Polymorphous adenocarcinoma||Disease||
|
|
|
|
Line 365: Line 365:
|
|
|-
|-
|[[BRST5:Tall Cell Carcinoma with Reversed Polarity|Tall Cell Carcinoma with Reversed Polarity]]||Disease||H. Evin Gulbahce
|[[BRST5:Tall Cell Carcinoma with Reversed Polarity|Tall cell carcinoma with reversed polarity]]||Disease||H. Evin Gulbahce
|8/11/2023
|8/11/2023
|10/11/2023
|10/11/2023
Line 374: Line 374:
|2021 template added
|2021 template added
|-
|-
|Neuroendocrine Tumour||Disease||
|Neuroendocrine tumour||Disease||
|
|
|
|
Line 383: Line 383:
|
|
|-
|-
|Neuroendocrine Carcinoma||Disease||
|Neuroendocrine carcinoma||Disease||
|
|
|
|
Line 430: Line 430:
|2021 template added
|2021 template added
|-
|-
|[[BRST5:Phyllodes Tumour|Phyllodes Tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
|[[BRST5:Phyllodes Tumour|Phyllodes tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
|8/11/2023
|8/11/2023
|11/11/2023
|11/11/2023
Line 459: Line 459:
----
----
|-
|-
|Syringomatous Tumour||Disease||
|Syringomatous tumour||Disease||
|
|
|
|
Line 468: Line 468:
|
|
|-
|-
|Nipple Adenoma||Disease||
|Nipple adenoma||Disease||
|
|
|
|
Line 477: Line 477:
|
|
|-
|-
|Paget disease of the Breast||Disease||
|Paget disease of the breast||Disease||
|
|
|
|
Line 524: Line 524:
|
|
|-
|-
|Atypical Vascular Lesions||Disease||
|Atypical vascular lesions||Disease||
|
|
|
|
Line 533: Line 533:
|
|
|-
|-
|Postradiation Angiosarcoma of the Breast||Disease||
|Postradiation angiosarcoma of the breast||Disease||
|
|
|
|
Line 542: Line 542:
|
|
|-
|-
|Primary Angiosarcoma of the Breast||Disease||
|Primary angiosarcoma of the breast||Disease||
|
|
|
|
Line 551: Line 551:
|
|
|-
|-
|Nodular Fasciitis||Disease||
|Nodular fasciitis||Disease||
|
|
|
|
Line 569: Line 569:
|
|
|-
|-
|Desmoid Fibromatosis||Disease||
|Desmoid fibromatosis||Disease||
|
|
|
|
Line 578: Line 578:
|
|
|-
|-
|[[BRST5:Inflammatory Myofibroblastic Tumour|Inflammatory Myofibroblastic Tumour]]||Disease||Yajuan Liu
|[[BRST5:Inflammatory Myofibroblastic Tumour|Inflammatory myofibroblastic tumour]]||Disease||Yajuan Liu
|8/11/2023
|8/11/2023
|11/11/2023
|11/11/2023
Line 605: Line 605:
|
|
|-
|-
|Granular Cell Tumour||Disease||
|Granular cell tumour||Disease||
|
|
|
|
Line 659: Line 659:
|
|
|-
|-
|Pseudoangiomatous Stromal Hyperplasia||Disease||
|Pseudoangiomatous stromal hyperplasia||Disease||
|
|
|
|
Line 688: Line 688:
----
----
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease||
|
|
|
|
Line 697: Line 697:
|
|
|-
|-
|Follicular Lymphoma||Disease||
|Follicular lymphoma||Disease||
|
|
|
|
Line 706: Line 706:
|
|
|-
|-
|Diffuse Large B-cell Lymphoma||Disease||
|Diffuse large B-cell lymphoma||Disease||
|
|
|
|
Line 715: Line 715:
|
|
|-
|-
|Burkitt Lymphoma||Disease||
|Burkitt lymphoma||Disease||
|
|
|
|
Line 724: Line 724:
|
|
|-
|-
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||
|Breast implant-associated anaplastic large cell lymphoma||Disease||
|
|
|
|
Line 762: Line 762:
|
|
|-
|-
|Carcinoma In Situ||Disease||
|Carcinoma in situ||Disease||
|
|
|
|
Line 771: Line 771:
|
|
|-
|-
|Invasive Carcinoma||Disease||
|Invasive carcinoma||Disease||
|
|
|
|
Line 780: Line 780:
|
|
|-
|-
|Metastases to the Breast||Disease||
|Metastases to the breast||Disease||
|
|
|
|
Line 809: Line 809:
----
----
|-
|-
|BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|BRCA1/2-associated hereditary breast and ovarian cancer syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 818: Line 818:
|N/A
|N/A
|-
|-
|Cowden Syndrome||Disease||
|Cowden syndrome||Disease||
|
|
|
|
Line 827: Line 827:
|NOT YET CREATED (not in GTS5) - See page "[[DIG5:Cowden syndrome|Cowden Syndrome]]" in DIG5 book. Will later add breast book link redirecting to this DIG5 book page (need to correlate with related volunteer page - [[DIG5:Volunteer Assignments and Opportunities]]).
|NOT YET CREATED (not in GTS5) - See page "[[DIG5:Cowden syndrome|Cowden Syndrome]]" in DIG5 book. Will later add breast book link redirecting to this DIG5 book page (need to correlate with related volunteer page - [[DIG5:Volunteer Assignments and Opportunities]]).
|-
|-
|Ataxia-Telangiectasia||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|Ataxia-telangiectasia||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 836: Line 836:
|N/A
|N/A
|-
|-
|Li-Fraumeni Syndrome, TP53-Associated||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|Li-Fraumeni syndrome, TP53-associated||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 845: Line 845:
|N/A
|N/A
|-
|-
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni Syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 854: Line 854:
|N/A
|N/A
|-
|-
|CDH1-Associated Breast Cancer||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|CDH1-associated breast cancer||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 863: Line 863:
|N/A
|N/A
|-
|-
|PALB2-Associated Cancers||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|PALB2-associated cancers||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 872: Line 872:
|N/A
|N/A
|-
|-
|Peutz-Jeghers Syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|Peutz-Jeghers syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 881: Line 881:
|N/A
|N/A
|-
|-
|Neurofibromatosis Type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
|Neurofibromatosis type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
|
|
|
|
Line 890: Line 890:
|NOT YET CREATED - See page "[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis Type 1 (NF1)]]" in GTS5 book. Will later add breast book link redirecting to this GTS5 book page (need to correlate with related volunteer page - [[GTS5:Volunteer Assignments and Opportunities]]).
|NOT YET CREATED - See page "[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis Type 1 (NF1)]]" in GTS5 book. Will later add breast book link redirecting to this GTS5 book page (need to correlate with related volunteer page - [[GTS5:Volunteer Assignments and Opportunities]]).
|-
|-
|[[BRST5:Polygenic Component of Breast Cancer Susceptibility|Polygenic Component of Breast Cancer Susceptibility]]
|[[BRST5:Polygenic Component of Breast Cancer Susceptibility|Polygenic component of breast cancer susceptibility]]
|Disease
|Disease
|Xiaolin Hu
|Xiaolin Hu

Revision as of 16:26, 12 July 2024

Welcome!

For assignments, please see the "Author" column below (highlighted blue).

If empty (no name is present), please volunteer to create content for that disease!

To volunteer, please [Contact us] with your page of interest.


WHO Classification of Tumours of the Breast (5th Edition) Content
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)
Usual ductal hyperplasia Disease
Columnar cell lesions, including flat epithelial atypia Disease
Atypical ductal hyperplasia Disease
Sclerosing adenosis Disease
Apocrine adenosis and adenoma Disease
Microglandular adenosis Disease
Radial scar/complex sclerosing lesion Disease
Tubular adenoma Disease
Lactating adenoma Disease
Ductal adenoma Disease
Pleomorphic adenoma Disease
Adenomyoepithelioma Disease
Malignant adenomyoepithelioma Disease
Intraductal papilloma Disease
Papillary ductal carcinoma in situ Disease
Encapsulated papillary carcinoma Disease
Solid papillary carcinoma (in situ and invasive) Disease
Invasive papillary carcinoma Disease
Atypical lobular hyperplasia Disease
Lobular carcinoma in situ Disease
Ductal carcinoma in situ Disease
Invasive breast carcinoma of no special type Disease
Microinvasive carcinoma Disease
Invasive lobular carcinoma Disease
Tubular carcinoma Disease
Cribriform carcinoma Disease
Mucinous carcinoma Disease
Mucinous cystadenocarcinoma Disease
Invasive micropapillary carcinoma Disease
Carcinoma with apocrine differentiation Disease
Metaplastic carcinoma Disease
Acinic cell carcinoma Disease Patricija Zot 2/28/2024 PENDING Katherine Geiersbach
Adenoid cystic carcinoma Disease Katherine Geiersbach / Jun Liao 10/12/02022 11/11/2023 COMPLETE Hui Chen / Katherine Geiersbach 12/6/2023 2021 template added
Secretory carcinoma Disease Hui Chen / Morteza Seifi 10/12/2022 11/11/2023 COMPLETE Katherine Geiersbach 2021 template added
Mucoepidermoid carcinoma Disease
Polymorphous adenocarcinoma Disease
Tall cell carcinoma with reversed polarity Disease H. Evin Gulbahce 8/11/2023 10/11/2023 COMPLETE Katherine Geiersbach 2021 template added
Neuroendocrine tumour Disease
Neuroendocrine carcinoma Disease
CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)
Hamartoma Disease
Fibroadenoma Disease H. Evin Gulbahce / Patricija Zot 8/11/2023 11/11/2023 PENDING 2021 template added
Phyllodes tumour Disease Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach 8/11/2023 11/11/2023 COMPLETE 2021 template added
CHAPTER 4 (TUMOURS OF THE NIPPLE)
Syringomatous tumour Disease
Nipple adenoma Disease
Paget disease of the breast Disease
CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)
Haemangioma Disease
Angiomatosis Disease
Atypical vascular lesions Disease
Postradiation angiosarcoma of the breast Disease
Primary angiosarcoma of the breast Disease
Nodular fasciitis Disease
Myofibroblastoma Disease
Desmoid fibromatosis Disease
Inflammatory myofibroblastic tumour Disease Yajuan Liu 8/11/2023 11/11/2023 COMPLETE Katherine Geiersbach 12/6/2023 2021 template added
Schwannoma Disease
Neurofibroma Disease
Granular cell tumour Disease
Leiomyoma Disease
Leiomyosarcoma Disease
Lipoma Disease
Angiolipoma Disease
Liposarcoma Disease
Pseudoangiomatous stromal hyperplasia Disease
CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) Disease
Follicular lymphoma Disease
Diffuse large B-cell lymphoma Disease
Burkitt lymphoma Disease
Breast implant-associated anaplastic large cell lymphoma Disease
CHAPTER 7 (TUMOURS OF THE MALE BREAST)
Gynaecomastia Disease
Carcinoma in situ Disease
Invasive carcinoma Disease
Metastases to the breast Disease
CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)
BRCA1/2-associated hereditary breast and ovarian cancer syndrome Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Cowden syndrome Disease NOT YET CREATED (not in GTS5) - See page "Cowden Syndrome" in DIG5 book. Will later add breast book link redirecting to this DIG5 book page (need to correlate with related volunteer page - DIG5:Volunteer Assignments and Opportunities).
Ataxia-telangiectasia Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Li-Fraumeni syndrome, TP53-associated Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Li-Fraumeni syndrome, CHEK2-associated Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
CDH1-associated breast cancer Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
PALB2-associated cancers Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Peutz-Jeghers syndrome Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Neurofibromatosis type 1 Disease Ngoni Faya (trainee) + Madina Sukhanova NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book. Will later add breast book link redirecting to this GTS5 book page (need to correlate with related volunteer page - GTS5:Volunteer Assignments and Opportunities).
Polygenic component of breast cancer susceptibility Disease Xiaolin Hu 6/4/2024 Template added (6/4/24)


Retrieved from "https://test.ccga.io/index.php?title=BRST5:Volunteer_Assignments_and_Opportunities&oldid=14644"